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Dogs with Canine Cognitive Dysfunction (CCD) accumulate amyloid beta (Aβ) in the
brain. As the cognitive decline and neuropathology of these old dogs share features with
Alzheimer’s disease (AD), the relation between Aβ and cognitive decline in animal models
of cognitive decline is of interest to the understanding of AD. However, the sensitivity of
the biomarker Pittsburgh Compound B (PiB) to the presence of Aβ in humans and in other
mammalian species is in doubt. To test the sensitivity and assess the distribution of Aβ in
dog brain, we mapped the brains of dogs with signs of CCD (n=16) and a control group
(n=4) of healthy dogs with radioactively labeled PiB ([11C]PiB). Structural magnetic reso-
nance imaging brain scans were obtained from each dog. Tracer washout analysis yielded
parametric maps of PiB retention in brain. In the CCD group, dogs had significant retention
of [11C]PiB in the cerebellum, compared to the cerebral cortex. Retention in the cerebel-
lum is at variance with evidence from brains of humans with AD. To confirm the lack of
sensitivity, we stained two dog brains with the immunohistochemical marker 6E10, which
is sensitive to the presence of both Aβ and Aβ precursor protein (AβPP). The 6E10 stain
revealed intracellular material positive for Aβ or AβPP, or both, in Purkinje cells. The brains
of the two groups of dogs did not have significantly different patterns of [11C]PiB binding,
suggesting that the material detected with 6E10 is AβPP rather than Aβ. As the compari-
son with the histological images revealed no correlation between the [11C]PiB and Aβ and
AβPP deposits in post-mortem brain, the marked intracellular staining implies intracellular
involvement of amyloid processing in the dog brain.We conclude that PET maps of [11C]PiB
retention in brain of dogs with CCD fundamentally differ from the images obtained in most
humans with AD.
Keywords: canine cognitive dysfunction, Alzheimer’s disease, Pittsburgh compound B, beta-amyloid, dog, 6E10
immunohistochemistry
INTRODUCTION
A prominent explanation of the etiology of Alzheimer’s disease
(AD) is the amyloid cascade hypothesis (Hardy and Selkoe, 2002;
Jack et al., 2010). According to this hypothesis, Aβ has a primary
role in the neuropathological changes associated with AD. The
deposition of Aβ is considered an early event in the pathogenesis
of AD, implying that suitable biomarkers of Aβ load would detect
early evidence of disease presence (McKhann et al., 2011).
Humans and dogs have coexisted in mutually beneficial part-
nerships for at least 100,000 years (Vila et al., 1997). Dogs develop
signs of behavioral disorder that correlate with neuropathologi-
cal findings, and aged dogs acquire behavioral deficits of spatial
awareness, social interaction, sleeping pattern, house training, and
memory and learning. This combination of behavioral symptoms
is known as Canine Cognitive Dysfunction (CCD) (Satou et al.,
1997; Rofina et al., 2006; Osella et al., 2007; Yu et al., 2011). The
decline of cognitive functions correlates with an increase of Aβ
deposits in the cerebral cortex of the dog (Colle et al.,2000; Pugliese
et al., 2006a; Rofina et al., 2006). The Aβ deposits found in dog
brains are primarily of the diffuse type and are of similar amino
acid sequence to those observed in humans (Head et al., 1998;
Sarasa et al., 2010). Dogs with CCD are therefore of special inter-
est as an animal model of the early events of AD, when Aβ deposits
mainly are of the diffuse type (Pugliese et al., 2006b; Rofina et al.,
2006).
A modified form of the amyloid-binding histological dye
thioflavin-T ([11C]PiB) made non-invasive PET imaging of amy-
loid deposits possible. Prior to this, visualization of Aβ deposits
was only possible using histological post-mortem material (Klunk
et al., 2004). Although new potential tracers are becoming available
[11C]PiB is the most intensively evaluated marker of Aβ in human
studies with PET (Klunk et al., 2004; Price et al., 2005; Mintun
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et al., 2006; Lockhart et al., 2007; Ikonomovic et al., 2008; Gulyas
et al., 2012; Gjedde et al., 2013; Rodell et al., 2013). Compared
to cognitively intact control subjects, AD patients exhibit greater
[11C]PiB retention in areas known to contain substantial accumu-
lations of Aβ deposits, including the frontal and parietal cortices,
whereas brain areas relatively unaffected by Aβ pathology, such as
the cerebellum, show little or no [11C]PiB retention (Klunk et al.,
2004; Price et al., 2005; Ikonomovic et al., 2008).
The specific binding properties of [11C]PiB are still contro-
versial, as is the correlation with the post-mortem histology of
tissue taken from disease models established in animals (Klunk
et al., 2005a; Toyama et al., 2005; Bacskai et al., 2007; Rosen et al.,
2011). The tracer is known to pass the blood-brain barrier with
comparative ease, which renders the uptake sensitive to blood flow
differences, as well as amyloid load (Blomquist et al., 2008; Gjedde
et al., 2013). Also, as a dye, Pittsburgh compound B (PiB) has
varying affinities for different tissue components and for different
multimeric assemblies of Aβ and Aβ precursor protein (AβPP).
Thus, PiB binding to specific subtypes of amyloid is at variance
with, and often much lower in mice and non-human primates,
than in humans, despite substantial Aβ deposits in these species
(Klunk et al., 2005b; Rosen et al., 2008; Manook et al., 2012).
According to Rosen et al. (2010), it is possible that PiB recognizes
a specific site in multimeric Aβ that is peculiar to most humans
with AD, but may be unavailable in some humans and in other
mammalian species.
It is not yet known whether tracer [11C]PiB detects Aβ deposits
in dogs. To test if the tracer actually detects Aβ deposits in a cohort
of dogs with a clinical diagnosis of CCD, in comparison with
unaffected control dogs, and thus effectively reveals the known dis-
tribution of Aβ in this species, we obtained [11C]PiB PET images
from the brains of animals in these two groups.
MATERIALS AND METHODS
According to the experimental design, PET images were obtained
from dog brains using an HRRT CPS Innovations tomograph, and
MR images were subsequently co-registered for each dog brain.
The binding capacity for each brain region was assessed by analy-
sis of regional washout rates. Immunohistochemical analysis was
performed on brain sections from two dogs using a monoclonal
mouse antibody against the amino acid residue 1–16 of Aβ (6E10).
The study population consisted of a group of dogs with a clin-
ical diagnosis of CCD (n= 16) and a control group of cognitively
normal dogs (n= 4). Dogs were recruited from the Small Animal
University Hospital at The Department of Clinical Veterinary and
Animal Sciences, University of Copenhagen or through referring
veterinarians.
The study was approved by the ethics committee at The Depart-
ment of Clinical Veterinary and Animal Sciences, Faculty of Health
and Medical Sciences, University of Copenhagen, Denmark.
CCD GROUP
The study population consisted of 16 geriatric dogs with a diag-
nosis of CCD, including nine males and seven females, with an
average age of 12.6 years (range 9–17 years; SD 2.2 years). All dogs
had a clinical and neurological examination, standard hemato-
logical and chemical profiles including thyroid panel showing no
evidence of systemic or neurological disease, which could mimic
clinical signs of CCD. All dogs had magnetic resonance imaging
(MRI) that showed no signs of intracranial lesions that might give
rise to clinical signs mimicking CCD. A clinical diagnosis of CCD
was established after evaluation with a validated owner question-
naire that targeted signs of CCD and was further supported by
the finding of significant brain atrophy on MRI images by means
of stereology [Cavalieri principle; (Kiatipattanasakul et al., 1996;
Rofina et al., 2006)].
CONTROL GROUP
The group of control dogs consisted of four dogs aged 5–12 years
(mean 8.8 years, SD 3.3), three males and one female. The dogs
had a normal clinical and neurological examination and standard
hematological and chemical profiles including thyroid panel and
showed no signs of systemic disease. All dogs had a normal MRI.
The dogs were defined as having normal cognitive behavior based
on absence of signs of CCD, as assessed by owner interviews, using
the same validated questionnaire used for the CCD group.
Details of the study group are listed in Table 1.
IMAGING PROCEDURES
PET images of the dog brains were obtained with the HRRT CPS
Innovations tomograph mainly used for animal model research.
Before PET, each dog was sedated with an intramuscular injection
of diazepam 0.4–0.7 mg/kg and methadone 0.2–0.4 mg/kg. Two
catheters were placed either in the cephalic or saphenous veins,
depending on accessibility, one for the combined administration
of anesthesia and maintenance fluids and one for the administra-
tion of [11C]PiB. Anesthesia was induced by intravenous injection
Table 1 | Information regarding age, sex, weight, and breed for the
study population.
Age Sex Weight (kg) Breed
CCD group 13 M 15.6 Beagle
13 M 2.7 Chihuahua
12 F 10.0 Cocker Spaniel
13 F 19.0 Tervueren
10 F 33.0 German Shepherd
11 M 12.2 Cairn Terrier
15 M 8.1 Dachshund
11 M 15.6 Catalonian sheepdog
17 M 12.5 Small mix
14 F 7.9 Jack Russell
9 M 28.0 Labrador
11 M 38.0 German Wirehaired Pointer
13 F 28.0 Labrador
13 F 22.0 Border Collie
11 M 20.0 Beagle
16 M 10.0 Kooikerhondje
Control group 7 M 30.0 Tervueren
11 M 31.0 Groenendal
5 M 26.5 Tervueren
12 F 21.0 Tervueren
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of propofol 4 mg/kg. Following intubation, anesthesia was main-
tained by a continuous rate infusion of propofol 4–6 mg/kg/h
(Grasby 3400 Anesthesia Pump, Groendorf Medicine, Hørsholm,
Denmark) and the dog was placed in dorsal recumbency with the
head positioned in the scanner field. Each dog was carefully posi-
tioned in a deflatable Kroeyer bag in order to minimize individual
positioning variability between scans. Respiration was maintained
with a ventilator (Hallowell EMC Model 200 Veterinary Anes-
thesia Ventilator, Hallowell EMC, Pittsfield, MA, USA), and heart
rate was monitored by ECG, Oxygen saturation through a pulse
oximeter and blood pressure through a pediatric blood pressure
cuff placed on one of the hind extremities. One monitor (MP-
9000 Mindray Patient Monitor, Shenzhen Mindray Bio-medical
Electronics Co., Hamburg, Germany) registered all parameters.
The dogs received Lactated Ringer’s solution from an infusion
pump (Baxter) throughout the anesthesia at a maintenance rate
of 10 ml/kg/h. All dogs were fasted for at least 12 h prior to imaging
to reduce anesthetic risk.
Each dog was injected intravenously with 84–333 MBq [N -
methyl-11C]2-(4′-methylaminophenyl)-6-hydroxybenzothiazole
([11C]PiB) dissolved in 10 ml of sterile isotonic saline. PET emis-
sion data were collected for 90 min preceded by a transmission
scan, commencing with the injection of [11C]PiB.
We used 30 min MRI with 3 T GE Signa HDxt – Twin speed
gradient system to obtain anatomical regions of interest (RIO)
(General Electric Medical Systems, Milwaukee, WI, USA). The
dogs were placed headfirst into the magnet bore, and an 8-channel
GE head coil was secured over the head of the animal. The scan-
ner allowed for acquisition of high-resolution anatomy imaging
in contiguous 1 mm thick transverse slices using three dimen-
sional spoiled gradient echo (SPGR), pulse sequence (TE= 2.9 ms,
TR= 6.7ms, flip angle= 14°).
GENERATION OF AN MR TEMPLATE BRAIN
No template is available for the co-registration of dogs to a
standard 3-D imaging volume, so we constructed a reference
template from the MRI anatomical image of one control dog
brain. For orientation purposes, the T1-weighted MRI volume
of the brain of this dog was linearly registered to an in-house
template space of Danish Landrace pigs. The registration was
performed using the MINC registration software package from
Montreal Neurological Institute (MNI) (Collins et al., 1994). This
pig atlas was constructed as described in previous investigations
(Maes et al., 1997; Watanabe et al., 2001; Andersen et al., 2005).
This control dog brain image was used as a reference space for
the subsequent intersubject co-registration of all dog brains in
the study. For each dog, the T1-weighted MRI brain volume
was manually cropped to initially remove extracerebral tissue,
and the image was corrected for non-uniformity in the image
intensity (Sled et al., 1998). The MR-image was then registered
to the dog model space using a 12 parameter affined trans-
formation (Maes et al., 1997). The images were resampled to
isotropic resolution of 0.5 mm 3-D resolution, the cerebral tis-
sue was skull-stripped using the registration, and a brain mask
defined on the dog template. We used this skull-stripped MRI
as a target for the subsequent MRI-PET registrations of dog
brains.
RECONSTRUCTION OF [11C]PiB IMAGES
For each PET image, the dynamic files were averaged over the
time dimension and the average image was blurred using a Gauss-
ian kernel to a full width at half maximum (FWHM) of 4.0 mm.
The blurred image was then linearly registered using a rigid body
affined transformation and mutual information criteria (Collins
et al., 1994; Maes et al., 1997). Each dynamic and averaged PET
image was spatially normalized using the corresponding concate-
nated transform from PET to MRI to model space. This spatial
normalization was performed using the MNI software package.
As no consensus exists on the specific anatomic localization of
the different canine brain cortical regions, we used a segregation
of cortical regions that largely agrees with the canine stereotaxic
brain anatomy atlas (Dua-Sharma et al., 1970).
IDENTIFICATION OF BRAIN REGIONS
In order to extract image values for relevant regional brain areas,
we manually segmented the model dog brain image into spe-
cific RIO, which included cortical regions and the cerebellum;
frontal, temporal, parietal, and occipital cortices and the cerebel-
lum (Figure 1), with initial tissue segmentation of gray matter,
white matter, and CSF classes with an automated method (Cocosco
et al., 2003). We then manually parcellated each image into the rele-
vant regions for each tissue class and obtained regional parametric
estimates of PiB binding from each of these template regions.
PARAMETRIC MAPPING OF PiB RETENTION
The brain uptake of [11C]PiB largely is flow-limited, with an
extraction fraction of more than 50% (Blomquist et al., 2008).
Therefore, we determined the binding capacity by analysis of
regional washout rates, which decline in the presence of binding
(Moller et al., 2009). We used washout analysis because unmetab-
olized [11C]PiB disappears rapidly from the circulation and the
consequent brief exchange with brain tissue implies that retention
of intact tracer in brain tissue depends on the washout rate and
not on a continued exchange between compartments of tracer in
the tissue and circulation after the period of initial entry of tracer
into the tissue, which ends approximately at 4 min after injection
(Rodell et al., 2013). Also, we chose this method because we ini-
tially had no evidence of the presence of a specific reference region
devoid of displaceable binding of [11C]PiB in dog brain.
To parametrically map neuroreceptors in relevant cases, a refer-
ence region eliminates the need to determine the arterial concen-
trations of the tracer, particularly when tracer retention is subject
washout limitation only (Edison et al., 2012). In brain, amyloid
deposits are present in the cerebellum in genetic AD, as cerebral
amyloid angiopathy, but also in prion diseases (Villemagne et al.,
2012). The choice of an alternative method of identification of
a reference region for the analysis of [11C]PiB binding therefore
was necessary in the present case (Moller et al., 2009; Edison et al.,
2012). The chosen method specifically applies to tracers with the
kinetic behavior of PiB. It identifies a suitable reference region in
the brain when one exists, by locating the area of least [11C]PiB
binding, considered most suitable for this purpose.
Using the in-house developed software, we extracted mean
[11C]PiB binding values within specific ROIs from the parametric
images and submitted region-based analysis. Figure 1 shows the
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FIGURE 1 | Showing different sections of a dog brain with the ROI
as color coded areas outlined by the authors based on a stereotaxic
atlas by Dua-Sharma, in order to extract PET image values for
relevant regional brain areas (Dua-Sharma et al., 1970). (A) Sagittal
mid section of a dog brain with identification of ROI. (B) Dorsal section
of dog brain at the level of the third ventricle and caudate nucleus with
identification of ROI. (C)Transverse section of dog brain at the level of
the third and lateral ventricles and the habenular nucleus with
identification of ROI. Color code identifies the gray matter for each ROI
used. ROI, regions of interest.
ROIs used to extract the binding values. The binding potential
BPND of [11C]PiB was estimated from the washout measure, in
relation to the identified region of reference (Moller et al., 2009).
We chose the reference region by first locating the voxels of max-
imum washout rates, identified by means of the washout index
Θ that equals the ratio of the twice to once integrated time-
radioactivity records of tracer in the voxels. The faster the washout,
and hence the lower the specific binding, the higher the magnitude
of the washout index Θ (Moller et al., 2009).
HISTOLOGY AND IMMUNOHISTOCHEMISTRY
Two CCD dog brains underwent ex vivo histopathological inves-
tigation. After sacrifice, we quickly removed and immersed the
brains in 10% neutral buffered formalin until further pro-
cessing. From each brain, we embedded one hemisphere in
alginate and sectioned it coronally into 9 mm thick slabs as
directed by the previously obtained MRI/PET images (Sorensen
et al., 2000; Bjarkam et al., 2001). We immersed the brain
slabs in 30% sucrose for 5 days, froze them with gaseous CO
mounted in a cryostat, and then sectioned them further into
20 series of 40µm thick coronal sections. The resulting sections
were mounted on microslides and subsequently stained with
Nissl-, AMG, HE, or Congo Red/Thioflavin S, according to stan-
dard protocols, or stored freely floating in De Olmos solution for
subsequent immunohistochemical staining procedures (Nielsen
et al., 2007). We performed immunohistochemical analysis on
the freely floating sections with a monoclonal mouse antibody
against the amino acid residue 1–16 of Aβ (6E10) (Cat # SIG-
39320) (Covance, CA, USA), which does not distinguish between
AβPP and Aβ (Aho et al., 2010). We pretreated sections for 10 min
with 70% formic acid to expose antigenic sites and then incubated
the sections in primary antibody diluted 1:2000 in Tris buffered
saline with 1% Triton +0.2% milk overnight at 4°C, before visu-
alization with a secondary goat anti-mouse IgG diluted 1:400 in
Tris buffered saline with 1% Triton +0.2% milk for 1 h at room
temperature. We visually assessed the staining by light microscopy
of 6E10-immunostained sections from the cerebral cortex and the
cerebellum.
STATISTICAL ANALYSIS
We analyzed differences among ROI estimates of [11C]PiB bind-
ing in both gray and white matter with paired-to-sample t -test.
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Group differences were tested with permutation tests, due to the
small sample size in the control group, in whole brain, as well as in
specific cortical regions. Due to the age span of the cohort, we also
assessed group differences after correction for age with regression
analysis. A probability of p< 0.05 was considered a statistically
significant non-random result.
RESULTS
In the CCD group [11C]PiB binding was significantly higher in the
gray matter of the cerebellum, than in the frontal (p< 0.001), tem-
poral (p< 0.001), parietal (p< 0.001), and occipital (p< 0.001)
lobes. Thus, the voxel maps of the washout index (Θ(T )) values
did not confirm the prediction of the cerebellum as a suitable ref-
erence region. We chose the reference area to be all voxels in which
the value of Θ equaled or exceeded 95% of the maximum value of
Θ (2170 s). Surprisingly, we found this reference region to be sit-
uated in the temporal cortex (Figure 2). Greater PiB binding was
seen in the gray matter of the occipital lobe, compared with the
frontal and temporal lobes, with p= 0.03 and p= 0.003, respec-
tively, for these comparisons. In addition, the [11C]PiB reached
significantly higher binding in the gray matter in the parietal lobe
than in the temporal lobe (p< 0.001) (Table 2). The maps revealed
differential regional [11C]PiB binding, with the highest binding in
the cerebellum.
FIGURE 2 | Magnetic resonance imaging of the brain of CCD dogs with
reference region of max average theta value (red/dark red) identical with
an area of maximal washout characteristics of [11C]PiB highlighted in
red and therefore minimum binding of [11C]PiB. (A) Mid-sagittal section of
dog brain showing an area of max theta value (red/dark red) and therefore
minimum [11C]PiB binding in the thalamic adhesion and the cerebellum.
(B) Dorsal section of dog brain at the level of the third ventricle and caudate
nucleus. Showing areas of max theta value (red/dark red) in the parietal and
temporal lobes. (C)Transverse section of dog brain at the level of the third
and lateral ventricles and the habenular nuclei. Identifying areas of maximum
theta (red/dark red) and therefore minimum [11C]PiB binding in the temporal
lobes and the thalamic adhesion.
Table 2 | Mean BPND for [11C]PiB in different ROI determined by the Hypotime method for gray and white matter in the CCD group.
Cerebellum Frontal cortex Temporal cortex Parietal cortex Occipital cortex
Gray matter (mean BPND) 0.35 0.23 0.22 0.24 0.26
Cerebellum vs. other ROI (p<) 0.001 0.001 0.001 0.001
White matter (mean BPND) 0.39 0.23 0.25 0.24 0.25
Cerebellum vs. other ROI (p<) 0.001 0.001 0.001 0.001
BPND, binding potential; PiB, Pittsburg compound B; CCD, canine cognitive dysfunction; ROI, regions of interest.
p-Values for difference in mean BPND between different ROI.
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Table 3 | showing mean BPND for [11C]PiB determined by the Hypotime method.
ROI
Dog id
Cerebellum
Gray
matter
Mean BPND
Cerebellum
White
matter
Mean BPND
Frontal
lobe
Gray
matter
Mean BPND
Frontal
lobe
White
matter
Mean BPND
Temporal
lobe
Gray
matter
Mean BPND
Temporal
lobe
White
matter
Mean BPND
Parietal
lobe
Gray
matter
Mean BPND
Parietal
lobe
White
matter
Mean BPND
Occipital
lobe
Gray
matter
Mean BPND
Occipital
lobe
White
matter
Mean BPND
CCD GROUP
1108 0.36918 0.41686 0.25736 0.27780 0.23450 0.27309 0.28551 0.29090 0.32647 0.32177
3252 0.29433 0.33419 0.22862 0.22355 0.21422 0.25950 0.24485 0.22384 0.21768 0.22302
18361 0.43665 0.34678 0.39350 0.37690 0.41874 0.38073 0.39839 0.34483 0.32867 0.20188
24503 0.36242 0.37585 0.30868 0.33663 0.39035 0.39897 0.36618 0.38278 0.33793 0.39035
27168 0.38462 0.51318 0.19780 0.20738 0.16561 0.21138 0.19474 0.20348 0.20727 0.22843
27055 0.28487 0.29230 0.24726 0.24043 0.18862 0.19913 0.22122 0.19580 0.24063 0.22283
27777 0.37050 0.50813 0.16553 0.15198 0.16889 0.17265 0.16966 0.16724 0.21399 0.21677
26494 0.30800 0.28431 0.19754 0.16082 0.15024 0.16348 0.17263 0.16019 0.17932 0.16612
26281 0.16585 0.17314 0.15036 0.11858 0.15762 0.16479 0.20272 0.19863 0.20245 0.24843
27123 0.52081 0.55678 0.37785 0.38499 0.46538 0.55397 0.53145 0.54140 0.46887 0.48173
29415 0.32971 0.42708 0.19442 0.20514 0.14215 0.15619 0.17425 0.17719 0.17228 0.15003
24324 0.49174 0.71424 0.29807 0.30279 0.31701 0.40795 0.33796 0.34689 0.41262 0.34943
23620 0.28615 0.25388 0.16042 0.15720 0.13067 0.14567 0.14248 0.12801 0.22083 0.19170
26410 0.32704 0.41380 0.13108 0.12207 0.11948 0.15642 0.11477 0.09918 0.19422 0.15573
20041 0.28830 0.26793 0.18012 0.15675 0.13928 0.15471 0.15767 0.14654 0.16238 0.15333
29165 0.36743 0.40270 0.20472 0.21982 0.18953 0.23377 0.20293 0.21934 0.26152 0.24769
CONTROL GROUP
31036 0.25143 0.31536 0.17511 0.18550 0.12698 0.15761 0.17070 0.18368 0.18761 0.19417
31097 0.32839 0.48010 0.27697 0.26922 0.21317 0.29735 0.26637 0.28353 0.29711 0.28859
31140 0.36561 0.37084 0.26716 0.30053 0.19079 0.23095 0.27198 0.26645 0.26197 0.26120
27351 0.26679 0.28976 0.19716 0.18982 0.14679 0.17281 0.17080 0.15745 0.20649 0.18540
BPND. Mean binding potential of [11C]PiB calculated using the Hypotime method.
FIGURE 3 | Correlation of MRI [11C]PiB PET imaging and
histopathology of a transverse brain section at the level of the rostral
commissure and the corpus striatum. The brain is from a 17-year old
small mixed breed male dog with clinical diagnosis of CCD. (A)Transverse
MRI of brain from CCD dog at the level of rostral commissure and the
corpus striatum (B) MRI from picture 1 and corresponding [11C]PiB PET
imaging. [11C]PiB binding is indicated by a color scale with red indicating
high retention and black indicating low retention. Calculated using the
Hypotime method. (C) Corresponding section to 1 and 2 immunostained
with amyloid (Aβ) monoclonal antibody 6E10. Dark areas identifies positive
areas of immunostaining using 6E10 indicating and thereby either Aβ and
AβPP deposits or both (Marked with arrows). MRI, magnetic resonance
imaging; PiB, Pittsburgh compound B; PET, positron emission tomography;
CCD, canine cognitive dysfunction.
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For white matter, significantly higher [11C]PiB binding
occurred in the cerebellum compared to the frontal, temporal,
parietal, and occipital lobes (p< 0.001) (Table 2), with mean esti-
mates of [11C]PiB binding potentials (BPND) listed in Table 3 for
all ROIs.
We found no significant differences of [11C]PiB binding
between the CCD and control groups in any ROI. Neither did we
find any correlation between the in vivo [11C]PiB accumulation in
images obtained with PET, and the ex vivo matched measures of
Aβ and AβPP staining post-mortem (Figure 3), consistent with the
observation that neocortex had very little signal from [11C]PiB, in
contrast to the extensive immunohistochemical staining of diffuse
extracellular Aβ and AβPP deposits (Figure 4). The one region of
the brain that did have significant labeling with [11C]PiB, the cere-
bellum, also had marked intracellular staining of Aβ or AβPP, or
both, in the Purkinje cells, and diffuse Aβ and AβPP staining of the
granule cell and molecular layers (Figure 5). The two dogs with
immunohistochemical staining did not show any Nissl, AMG, HE,
or Congo Red/Thioflavin positive amyloid deposits.
DISCUSSION
We present the first evidence that PET images of the distribution
of [11C]PiB retention in brain of dogs with CCD fundamentally
are different from the images obtained in most humans with AD.
Unlike the general evidence of uptake in brain of humans with AD,
the evidence in this study revealed the highest uptake in the cere-
bellum of the dogs with CCD and not in the neocortical regions.
We noted the least retention of the biomarker in the temporal cor-
tex (Figure 2). To obtain this finding, we mapped unto the brain
images an index of the biomarker washout, the washout index Θ,
FIGURE 4 | Histological sagittal sections of the frontal and temporal
lobes including the hippocampus. Sections are immunostained with
amyloid (Aβ) monoclonal antibody 6E10 (A,B) are histological section from the
frontal and temporal lobe, respectively. Obtained from a 17-year old small
mixed breed with signs of cognitive dysfunction. The sections exhibit diffuse
staining of cortical gray matter in the frontal and temporal cortex and marked
staining of the perforant pathway in the hippocampus. (C,D) are histological
section from the frontal and temporal lobe, respectively. Obtained from a
13-year old collie with signs of cognitive dysfunction. The sections exhibit
diffuse staining of the cortical gray matter in the frontal and temporal cortex.
The perforant pathway in the hippocampus only demonstrate marked staining
in a very small area compared to (B).
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FIGURE 5 | Histological horizontal sagittal sections through the
anterior lobe of the cerebellum. Obtained from a 13-year old
female Border Collie with clinical signs of canine cognitive
dysfunction. (A,B) Low magnification view immunostained with
amyloid (Aβ) monoclonal antibody 6E10 showing the presence of
marked immunostaining of Purkinje cells (black arrows), but also
exhibiting diffuse staining of the granular and molecular layer (white
arrows). (C,D) High magnification view of Purkinje cells in
(A,B) showing intracellular accumulation of Aβ positive material.
CCD, canine cognitive dysfunction.
which rises with the rate of washout. From the retention of the
biomarker, we concluded that the cerebellum gray matter in the
dog brain would not be an appropriate reference region for bind-
ing of [11C]PiB in dogs, a finding that is at variance with studies of
human AD, in whom the cerebellum shows little [11C]PiB bind-
ing and is an appropriate reference region (Klunk et al., 2004;
Ikonomovic et al., 2008; Rodell et al., 2013).
Comparison with the images of the histological material
revealed no correlation between the images of [11C]PiB and the Aβ
and AβPP deposits in post-mortem brain, despite marked intracel-
lular staining of Aβ/AβPP in the Purkinje cells and diffuse staining
of the granule and molecular cell layers. The marked intracellular
staining implies intracellular involvement of amyloid processing
in the dog brain (Figure 5).
We used the washout-dependent time variableΘ to identify an
alternative region of reference and to calculate binding potentials.
The key to the analysis is the time variableΘ,which is related to and
serves as an index of the rate of washout and hence of the degree
of expansion of the apparent volume of distribution of the tracer
occasioned by binding. By this approach, we found areas of rapid
clearance in small areas of the temporal cortex (Figure 2), which
we chose as regions of reference. As defined by us, the borders
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of the reference region enclosed an area in which the values of
Θ equaled or exceeded 95% of the maximum mean value of the
time variable Θ of 2170 s. This reference was used throughout the
subsequent analysis to determine the binding potentials relative to
non-displaceable accumulation (BPND).
We did note diffuse Aβ/AβPP immunostaining of both frontal
and temporal cortices with 6E10, however these deposits did not
bind [11C]PiB to the same degree as the deposits in the cerebel-
lum, implying that dogs with CCD are not afflicted with a typical
form of AD (Figure 4). Because the major part of amyloid is not
usually found in cerebellum of humans with AD, unlike in the
brains of the present group of CCD dogs, CCD may instead be
a better model of genetic AD in humans, or hereditary cerebral
hemorrhage with amyloidosis and prion diseases, also in humans
(Watanabe and Duchen, 1993; Ghiso and Frangione, 2001; Klunk
et al., 2007). However, these hypotheses are speculative and yet to
be confirmed in families of dogs.
The high degree of [11C]PiB binding in the cerebellum, with
few if any extracellular deposits and large amounts of intracellu-
lar Aβ or AβPP, or both, suggests that [11C]PiB binding may be
used to distinguish between intracellular Aβ and AβPP deposits in
the dog cerebellum. Aged dogs with CCD spontaneously exhibit
diffuse Aβ deposits in the cerebral cortex that are similar to those
found in early AD brains (Cummings et al., 1993, 1996; Satou
et al., 1997; Anderson et al., 2000; Head et al., 2008; Yu et al.,
2011). In addition, the diffuse Aβ deposits in the canine brain are
immunopositive for Aβ1–42 and do not stain with Congo red and
thioflavine, unlike proven cerebral amyloid angiopathy (Uchida
et al., 1992; Cummings et al., 1993, 1996; Satou et al., 1997).
The high proportion of diffuse to compact Aβ deposits in dogs
with CCD theoretically should not pose a problem, because previ-
ous investigations show that [11C]PiB in tissue from AD patients
also recognizes diffuse Aβ deposits in addition to compact Aβ
deposits (Klunk et al., 2003; Lockhart et al., 2007). Hence [11C]PiB
in principle would be a tracer suitable for outlining the distribu-
tion of Aβ deposits in the aged dog with CCD with a cranial to
caudal distribution. The results point to a pattern of [11C]PiB
retention in the dog brain, which is occasionally seen in humans.
We also found a discrepancy between the distributions of Aβ and
AβPP, when we visually correlated [11C]PiB images with regionally
matched images of the post-mortem histological material stained
with 6E10. In a study of a cohort of 10 AD patients, one patient
who met the histopathological criteria for AD had PiB-refractory
PET images (Rosen et al., 2010). This patient had more vascular
Aβ, higher levels of insoluble Aβ1–40 and Aβ1–42, and a higher ratio
of Aβ1–40 to Aβ1–42, compared to brain tissue from the nine other
AD patients.
Studies of [11C]PiB imaging in PS1/APP mice and post mortem
histological analysis have shown diverging results of different
attempts to find a correlation between the [11C]PiB images and
Aβ deposits in vitro (Klunk et al., 2005a; Manook et al., 2012).
The negative results may be explained in part by the presence of
lower affinity PiB binding sites on Aβ deposits in the transgenic
mouse brains than in AD brains (Klunk et al., 2005a; Toyama et al.,
2005). This explanation implies that a part of the PiB binding in
mouse and dog brains may be selective for a specific conforma-
tion of Aβ deposits found in AD patients at the low nanomolar
concentrations used in PET studies. This hypothetical selectivity
of PiB is consistent with another study of transgenic mice, in which
it was concluded that the detectability of amyloid by PiB depends
on the accumulation of specific Aβ subtypes. This explanation was
proposed as well in a study of primate brain homogenates, which
showed markedly reduced binding to PiB compared to human
brain homogenates (Rosen et al., 2011).
This study gave evidence that the distribution of [11C]PiB
retention in dogs with CCD fundamentally is different from that
seen in humans with AD. The results of the study support previ-
ous studies showing that [11C]PiB is a complex tracer in animals
and humans and more investigations of this radiotracer, including
displacement studies are needed.
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